Aquestive Therapeutics (NASDAQ:AQST) Shares Down 6.4% - Time to Sell?

Key Points

• Aquestive Therapeutics (NASDAQ:AQST) shares fell by 6.4%, trading at $5.08, with a total volume decrease of 32% from its average trading session.
• Despite the stock's decline, several brokerages have raised their target prices and ratings, with Oppenheimer increasing their target from $7.00 to $8.00 and maintaining an "outperform" rating.
• The company's latest earnings report indicated a loss of ($0.14) EPS, which was better than analysts' expectations of ($0.18), but revenues of $10 million fell short of the consensus estimate.

Aquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) shares traded down 6.4% on Monday . The stock traded as low as $5.10 and last traded at $5.08. 1,090,556 shares were traded during mid-day trading, a decline of 32% from the average session volume of 1,606,715 shares. The stock had previously closed at $5.42.

Analyst Ratings Changes

Several brokerages recently commented on AQST. Oppenheimer lifted their target price on shares of Aquestive Therapeutics from $7.00 to $8.00 and gave the stock an "outperform" rating in a research note on Monday. Lifesci Capital upgraded Aquestive Therapeutics to a "strong-buy" rating in a research note on Wednesday, September 3rd. HC Wainwright reiterated a "buy" rating and issued a $10.00 target price on shares of Aquestive Therapeutics in a research report on Tuesday, June 17th. Finally, Zacks Research upgraded Aquestive Therapeutics from a "strong sell" rating to a "hold" rating in a report on Wednesday, August 13th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, Aquestive Therapeutics presently has an average rating of "Buy" and an average target price of $10.29.

Aquestive Therapeutics Stock Down 6.9%

The company has a market cap of $503.09 million, a price-to-earnings ratio of -7.22 and a beta of 1.82. The business has a 50-day simple moving average of $3.98 and a two-hundred day simple moving average of $3.25.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last announced its quarterly earnings data on Monday, August 11th. The company reported ($0.14) EPS for the quarter, beating analysts' consensus estimates of ($0.18) by $0.04. The firm had revenue of $10.00 million during the quarter, compared to the consensus estimate of $11.32 million. Aquestive Therapeutics has set its FY 2025 guidance at EPS. As a group, equities analysts anticipate that Aquestive Therapeutics, Inc. will post -0.46 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Summit Wealth & Retirement Planning Inc. purchased a new stake in Aquestive Therapeutics in the first quarter worth about $29,000. Victory Capital Management Inc. bought a new stake in Aquestive Therapeutics during the 1st quarter valued at about $31,000. BNP Paribas Financial Markets raised its holdings in shares of Aquestive Therapeutics by 78.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company's stock valued at $31,000 after purchasing an additional 4,134 shares in the last quarter. Cambridge Investment Research Advisors Inc. purchased a new position in shares of Aquestive Therapeutics in the 1st quarter worth approximately $33,000. Finally, USAdvisors Wealth Management LLC purchased a new stake in shares of Aquestive Therapeutics in the 2nd quarter valued at $33,000. 32.45% of the stock is currently owned by hedge funds and other institutional investors.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.